<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880658</url>
  </required_header>
  <id_info>
    <org_study_id>GIHSYSU03</org_study_id>
    <nct_id>NCT01880658</nct_id>
  </id_info>
  <brief_title>Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer</brief_title>
  <acronym>CAMCO</acronym>
  <official_title>Phase II Clinical Trial: Capecitabine Maintenance Therapy in Colorectal Cancer Patients With Stage IIIC and R0-R1 Resected Stage IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Surgical resection and adjuvant therapy has become the main treatment for&#xD;
      resectable colorectal cancer. Treatment with current strategies, however,recurrent rate is&#xD;
      high for stage IIIC or R0 resected stage IV. The efficacy and safety of maintenance therapy&#xD;
      with capecitabine is still unknown.&#xD;
&#xD;
      PURPOSE: This single arm study is exploring surgical resection and adjuvant chemotherapy&#xD;
      followed by maintenance therapy with capecitabine to see the efficacy and safety, then to&#xD;
      investigate the effect of maintenance therapy for stage IIIC or R0 resected stage IV&#xD;
      colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES Primary evaluate the disease free survival rate of three years in patients with&#xD;
      stage IIIC or resectable stage IV colorectal cancer treated with maintenance capecitabine.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        1. Evaluate the over all survival time in patients treated with these regimens.&#xD;
&#xD;
        2. Correlate genetic patterns and the presence or absence of specific tissue biomarkers&#xD;
           with response and prognosis in patients treated with these regimens.&#xD;
&#xD;
        3. Determine quality of life (QOL) of patients treated with maintenance capecitabine versus&#xD;
           chemotherapy termination.&#xD;
&#xD;
        4. Determine the toxic effects of maintenance regimens in these patients.&#xD;
&#xD;
        5. Determine the convenience of care in patients treated with maintenance regimens.&#xD;
&#xD;
      OUTLINE: This is a single arm, single-enter study. Patients are receiving therapies as below.&#xD;
&#xD;
      Patients undergo R0-R1 resection and receive adjuvant chemotherapy oxaliplatin with&#xD;
      fluorouracil (5FU) and folinic acid（FOLFOX）or oxaliplatin with oxaliplatin with&#xD;
      capecitabine(capox) for no less than 4 months. Radiotherapy may be applied for patients with&#xD;
      rectal cancer if clinicians suspect that is necessary. Then patients receive oral&#xD;
      capecitabine for 12 months maintenance.&#xD;
&#xD;
      Quality of life is assessed at completion of adjuvant treatment, at completion of maintenance&#xD;
      chemotherapy , and at 1 year after maintenance chemotherapy.&#xD;
&#xD;
      After completion of adjuvant treatment, patients are followed every 3 months for 2 years, and&#xD;
      then every 6 months for 3years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 3 years.&#xD;
&#xD;
      Eligibility Ages Eligible for Study: 18-80 Years old Genders Eligible for Study: Both Accepts&#xD;
      Healthy Volunteers: No&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival rate(DFS)</measure>
    <time_frame>36 months</time_frame>
    <description>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Over all survival,genetic patterns, quality of life, toxic effects, convenience</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate the over all survival time in patients treated with these regimens.&#xD;
Correlate genetic patterns and the presence or absence of specific tissue biomarkers with response and prognosis in patients treated with these regimens.&#xD;
Determine quality of life (QOL) of patients treated with maintenance capecitabine versus chemotherapy termination.&#xD;
Determine the toxic effects of maintenance regimens in these patients.&#xD;
Determine the convenience of care in patients treated with maintenance regimens.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo R0-R1 resection and receive adjuvant chemotherapy FOLFOX or Capox for no less than 4 months. Radiotherapy may be applied for patients with rectal cancer if clinicians suspect that is necessary. Then patients receive oral capecitabine for 12 months maintenance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)</description>
    <arm_group_label>Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Adenocarcinoma of the colon or rectum&#xD;
&#xD;
          2. Age:18-80 years old&#xD;
&#xD;
          3. Received curative resection when diagnosed as colorectal cancer, postoperative stage:&#xD;
             IIIC OR IV(R0 resected)&#xD;
&#xD;
          4. Adjuvant chemotherapy with mFOLFOX6 or XELOX for more than four months 5.15 days prior&#xD;
             recruit, meet the following criteria:&#xD;
&#xD;
               -  Hematopoietic&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2 times ULN&#xD;
&#xD;
               -  Aspartate transaminase ≤ 2.5 times ULN&#xD;
&#xD;
               -  Alanine transaminase ≤ 2.5 times ULN&#xD;
&#xD;
               -  No hepatic disease that would preclude study treatment or follow-up&#xD;
&#xD;
               -  No uncontrolled coagulopathy&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
               -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
               -  No renal disease that would preclude study treatment or follow-up&#xD;
&#xD;
        6.The ECOG scores: 0～1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other colorectal cancers (i.e.sarcoma,lymphoma,carcinoid,squamous cell carcinoma,or&#xD;
             cloacogenic carcinoma)&#xD;
&#xD;
          2. Synchronous cancer of other site&#xD;
&#xD;
          3. Hypersensitivity to capecitabine&#xD;
&#xD;
          4. No More than 4 weeks since prior participation in any investigational drug study&#xD;
&#xD;
          5. Clear indication of involvement of the pelvic side walls by imaging With distant&#xD;
             metastasis&#xD;
&#xD;
          6. History of invasive rectal malignancy, regardless of disease-free interval Fertile&#xD;
             patients must use effective contraception&#xD;
&#xD;
          7. Uncontrolled hypertension&#xD;
&#xD;
          8. Cardiovascular disease that would preclude study treatment or follow-up&#xD;
&#xD;
          9. Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper&#xD;
             gastrointestinal tract bleeding&#xD;
&#xD;
         10. Pregnant or nursing, Fertile patients do not use effective contraception&#xD;
&#xD;
         11. Other malignancy within the past 5 years except effectively treated squamous cell or&#xD;
             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or&#xD;
             carcinoma in situ of the colon or rectum&#xD;
&#xD;
         12. No psychiatric or addictive disorders, or other conditions that, in the opinion of the&#xD;
             investigator, would preclude study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhong Deng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanhong Deng, MD</last_name>
    <phone>008613925106525</phone>
    <email>13925106525@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastrointestinal Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanhong Deng, MD</last_name>
      <phone>008613925106525</phone>
      <email>13925106525@163.com</email>
    </contact>
    <investigator>
      <last_name>Yanhong Deng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>February 8, 2014</last_update_submitted>
  <last_update_submitted_qc>February 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanhong Deng</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>Maintenance therapy</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>Post-operation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

